

EPIX MEDICAL INC  
Form 8-K  
March 11, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 7, 2003**

## EPIX MEDICAL, INC.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-21863**  
(Commission  
File Number)

**04-3030815**  
(IRS Employer  
Identification No.)

**71 Rogers Street**  
**Cambridge, Massachusetts 02142**  
(Address of principal executive offices) (Zip Code)  
Registrant's telephone number, including area code: (617) 250-6000

---

---

---

#### Item 5. Other Events.

On March 7, 2003, the Company announced that data from its second pivotal Phase III MS-325 clinical trial in patients with suspected vascular disease in the aortoiliac region were presented at the 2003 European Congress of Radiology Annual Scientific Session. The results of the trial demonstrated the potential clinical utility of MS-325-enhanced magnetic resonance angiography images in detecting vascular disease.

The press release announcing data from the Company's second pivotal Phase III MS-325 clinical trial is filed as an exhibit to this Form 8-K, and is incorporated by reference into this Item 5. The foregoing description of such document and the enrollment results contemplated therein is qualified in its entirety by reference to such exhibit.

#### Item 7. Financial Statements and Exhibits.

(c)  
Exhibits

99.1  
Press Release of the Company dated March 7, 2003

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EPIX MEDICAL, INC.**  
(Registrant)

Date: March 10, 2003

/s/ PEYTON J. MARSHALL

---

Peyton J. Marshall  
Senior Vice-President, Finance and  
Administration, Chief Financial Officer  
2

---

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release of the Company dated March 7, 2003

---

QuickLinks

[SIGNATURES](#)

[Exhibit Index](#)